Pralidoxime

Summary

Pralidoxime (CHEMBL1420) is an approved small-molecule cholinergic drug (ATC V03AB04); indicated across 2 conditions including poisoning.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V03AB04
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 137.16 Da · C7H9N2O+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1420
Name	Pralidoxime
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4884
ChEBI	CHEBI:8354
ATC	V03AB04
Molecular formula	C7H9N2O+
Molecular weight	137.16
InChIKey	JBKPUQTUERUYQE-UHFFFAOYSA-O

SMILES: C[N+]1=CC=CC=C1C=NO

IUPAC name: N-[(1-methylpyridin-1-ium-2-yl)methylidene]hydroxylamine

ChEBI definition: A pyridinium ion that is 1-methylpyridinium substituted by a (hydroxyimino)methyl group at position 2.

Pharmacological roles (ChEBI): cholinergic drug, cholinesterase reactivator, antidote to organophosphate poisoning, antidote to sarin poisoning.

Also known as: Atnaa, Pralidoxime, Pralidoxime cation, Pralidoxime ion, pralidoxime, SID11112108, PRALIDOXIME, PRALIDOXIME IODIDE, PRALIDOXIME MESYLATE

Parent form; salt/anhydrous children: CHEMBL14577, CHEMBL748, CHEMBL2104739, CHEMBL3335073

Patent coverage: 1,079 distinct patent families (2,522 SureChEMBL compound mentions), from 5 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Thyrotropin receptor, Histamine H1 receptor, 3’,5’-cyclic-AMP phosphodiesterase 4D.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TSHR	6.2	Potency	631	nM	CHEMBL_ACT_3917322

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
poisoning	1	MONDO:0029000	EFO:0008546

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06111352	PHASE2	COMPLETED	Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime
NCT02040350	PHASE1	COMPLETED	Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).